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rognostic Biomarkers in
T-Segment Elevation
yocardial Infarction
Step Toward Personalized Medicine
r a Tool in Search of an Application?*
uigi M. Biasucci, MD, Roberta Della Bona, MD
ome, Italy
n recent years, much effort has been devoted to risk
tratification of patients with acute coronary syndromes
ACS), mainly focusing on patients with non–ST-segment
levation (NSTE)-ACS. In this category of patients, bio-
arkers have been proven to be useful for: 1) the trouble-
ome diagnosis; 2) therapeutic and strategic decision mak-
ng (guiding the choice of more potent therapies, the
ndication and timing of invasive treatment, or both); 3) the
ong-term prognostication; and 4) a better understanding of
he complex pathophysiological mechanisms (1–6). Scoring
ystems have been created that also include up to 3 biomar-
ers in addition to clinical variables (7). The studies pub-
ished in these fields have made the history and the fortune
f biomarkers in cardiology, leading, for example, to the
xtensive use of troponins and the recognition of inflam-
ation as a fundamental player in plaque rupture.
See page 29
In ST-segment elevation myocardial infarction (STEMI),
owever, the main focus of interest has been the shortening
f time from onset of symptoms to treatment, with relatively
oor interest in prognostication, including biomarkers. In
n era of high in-hospital mortality for STEMI, this
osition was reasonable on various grounds. First, the
iagnosis and acute management of STEMI was considered
o be simple compared with non–STEMI, with the main
ecision (whether to proceed to immediate revasculariza-
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T-segment elevation and symptoms. Moreover, the prog-
osis of STEMI patients (excluding shock cases) who are
evascularized promptly with primary percutaneous coro-
ary intervention in a tertiary center is widely (but errone-
usly) perceived as being good, difficult to improve in the
ong term, and largely dependent on the efficacy of reper-
usion (8). However, the striking reduction in acute mor-
ality in STEMI, the still unacceptable rate of recurrent
vents after ACS, including STEMI, and the growing
vidence that not all ST-segment elevation syndromes are
schemic myocardial infarctions are undoubtedly going to
aise the interest for biomarkers in STEMI.
In this issue of the Journal, Damman et al. (9) address the
ole of biomarkers in STEMI. In their paper, many of these
ssumptions are tackled and somewhat disproved. First,
-year mortality of this real-world, relatively low-risk pop-
lation (shock patients and those undergoing rescue percu-
aneous coronary intervention were excluded; the mean
ymptoms-to-treatment time was relatively short, with most
atients undergoing primary percutaneous coronary inter-
ention within 2 to 5 h in a major tertiary center in the
etherlands) was almost 15%, comparing well with the
esults of other studies (10), but this result highlights
he need for a cumulative effort to improve survival in
TEMI, with appropriate treatment in the acute phase and
eyond. The main result, however, concerns the additional
rognostic value of a cohort of biomarkers (including
-reactive protein [CRP], N-terminal pro-brain natriuretic
eptide, cardiac troponin T, glucose, and estimated glomer-
lar filtration rate), which were shown (with the exclusion at
ultivariate analysis of cardiac troponin T and CRP) to
redict mortality and, when added to other, more estab-
ished, clinical variables, to improve their discriminatory
ower significantly.
These results, albeit novel and of potential clinical rele-
ance, because only a few and small studies have addressed
his topic, should be taken with caution and interpreted in
heir own context. At a careful reading, some methodolog-
cal limitations emerge, such as the high number of patients
xcluded from the final analysis (acknowledged by the
uthors in a fairly large limitations paragraph), and the
iased use of troponin and CRP. The non–high-sensitivity
ardiac troponin T assay used in this study does not allow
etection of troponin before 4 to 6 h from symptoms onset;
herefore, this assay could not detect increased levels of
roponin in a large part of the study population. Increase in
RP levels is detectable only 12 h after the onset of
ymptoms, whereas the cutoff value of 7 mg/l chosen by the
uthors is odd and different from what is recommended in
he literature (11). More importantly, although the multi-
ariate analysis confirms an independent prognostic value of
he 3 biomarkers, the discriminative value analysis shows
hat the addition of all the investigated biomarkers en bloc
esulted in an increment of discriminatory power compara-
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hus, it seems that these biomarkers in fact may represent
ifferent ways of looking at the same picture, reflecting a
ore general metabolic derangement characteristic of
igher-risk STEMI patients. Interestingly, a similar picture
lso is present in NSTE-ACS patients, underscoring the
athophysiological and clinical similarity of ACS as a
ontinuum (12). The importance of unspecific markers of
etabolic status (glucose), of left ventricular function and
euroendocrine activation (N-terminal pro-brain natriuretic
eptide), and of renal function (estimated glomerular filtra-
ion rate) in determining the risk of death in ACS patients
s in line with the unstable patient hypothesis and suggests
hat plaque rupture must be regarded as the consequence of
he overall patient health also in STEMI patients. It is
mpossible to prove this hypothesis on the basis of this
tudy, because an inherent limitation of such observational
tudies is the lack of exploration of plausible pathophysio-
ogical mechanisms and, more disturbing, because in this, as
n almost all other prognostic studies, the design of the
tudy and the database quality did not allow for separat-
ng mortality according to cause. That is, what is lacking,
ot only in the current study but also in general in the
iterature, is information on how many deaths are the
esult of recurrent infarction, how many are the result of
udden arrhythmic death, and how many are the result of
eart failure. Only this kind of information may allow us
o understand actual cause and effect and to design
ndividual prevention and treatment regimens for indi-
idual conditions. At variance from NSTE-ACS, in
hich survival curves—at least for N-terminal pro-brain
atriuretic peptide and renal function, as well as for
roponin and CRP—continue to diverge over time, in the
aper by Damman et al. (9), the curves generated using
rediction of risk by biomarkers diverge very early and
hen run almost parallel (see Fig. 1 of their paper [9]),
erhaps implying that these markers are informative in
articular for the early risk. This can be explained by the
rothrombotic and endothelium-damaging role of hyper-
lycemia and renal dysfunction in the acute phase
13,14), as well as by the more complex coronary anatomy
bserved in these conditions, and may recall and support
he notion that prognosis after STEMI largely depends
n efficacy of acute revascularization.
On this basis, the authors’ hypothesis that use of a
iomarker score may help to address the best therapies may
eem consequential. However, this may represent a danger-
us oversimplification: the step from higher nonspecific risk
o more aggressive specific therapy is long and should not be
onsidered until definitive data are provided. No new
reatments directly addressed to any of these biomarkers are
vailable yet. Specifically, renal function is a marker either of
ncreased ischemic and hemorrhagic risk, and therefore,
hoice of antithrombotic and antiplatelets agents should be
riven by the strength evidence or by specific tests, whereas
he effect of an anti-injury treatment with delta protein
1inase C inhibitors on biomarkers of damage has not been
roved (15).
In conclusion, Damman et al. (9) must be congratulated
or having reopened the interest for biomarkers in STEMI
nd for having pursued the goal of a more personalized
rognostication and therapy to improve outcome in this
opulation. The study provides important pathophysiolog-
cal information confirming the common roots of ACS,
ither ST-segment elevation or NSTE, and promising
linical improvements in STEMI treatment. Although their
fforts fell short of the objectives, we hope that they will
ontribute to a more accurate and individualized prognos-
ication and therapy, with consequent reduction in events
nd the flourishing of novel pathophysiological information.
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